Seminars in Hematology
Volume 41, Issue 1 , Pages 68-74 , January 2004

The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome

  • Masanori Matsumoto

      Affiliations

    • Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan
    • ,
  • Hideo Yagi

      Affiliations

    • Department of 2nd Internal Medicine, Nara Medical University, Nara, Japan
    • ,
  • Hiromichi Ishizashi

      Affiliations

    • Department of Health Science, Nara Medical University, Nara, Japan
    • ,
  • Hideo Wada

      Affiliations

    • Department of Clinical Laboratory, Mie University School of Medicine, Tsu, Japan
    • ,
  • Yoshihiro Fujimura

      Affiliations

    • Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan
    • Corresponding Author InformationAddress correspondence to Yoshihiro Fujimura, MD, Shijyo-cho 840, Kashihara City, Nara 634-8522, Japan

References 

  1. Moschcowitz E. Hyalin thrombosis of the terminal arterioles and capillaries (A hitherto undescribed disease). Proc NY Pathol Soc. 1924;24:21–24
  2. Bell WR. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse (Frequency, pathogenesis, and meaning). Semin Hematol. 1997;34:134–139
  3. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (The role of von Willebrand factor-cleaving protease). Best Pract Res Clin Haematol. 2001;14:437–454
  4. Moake JL. Thrombotic thrombocytopenic purpura (The systemic clumping “ plague”). Annu Rev Med. 2002;53:75–88
  5. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hämolytisch-urämische Syndrome (bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien). Schweiz Med Wochenschr. 1955;85:905–909
  6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584
  7. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  8. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063
  9. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, Nakagaki T, et al.  A novel human metalloprotease synthesized in the liver and secreted into the blood (Possibly, the von Willebrand factor-cleaving protease?). J Biochem. 2001;130:475–480
  10. Levy GG, Nichols WC, Lian E, Foroud T, McClintick JN, McGee BM, et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494
  11. Plaimauer B, Zimmermann K, Völkel D, Antonie G, Kerschbaumer R, Jenab P, et al.  Cloning, expression and characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100:3626–3632
  12. Lee T-P, Bouhassira EE, Lyubsky S, Tsai HM. ADAMTS13, the von Willebrand factor cleaving metalloprotease, is expressed in the perisinusoidal cells of the liver. Blood. 2002;100:497a; (abstr 1938)
  13. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89:3097–3103
  14. Kinoshita S, Yoshioka A, Park Y-D, Ishizashi H, Konno M, Funato M, et al.  Upshaw-Schulman syndrome revisited (A concept of congenital thrombotic thrombocytopenic purpura). Int J Hematol. 2001;74:101–108
  15. Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, et al.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–580
  16. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, et al.  A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869–872
  17. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood. 1960;14:943–957
  18. Upshaw JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med. 1978;298:1350–1352
  19. Fujimura Y, Matsumoto M, Yoshioka A, Matsui T, Titani K. von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol. 2002;75:25–34
  20. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocae J, et al.  Unusually large plasma factor VIII (von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura). N Engl J Med. 1982;307:1432–1435
  21. Yagi H, Konno M, Kinoshita S, Matsumoto M, Ishizashi H, Matsui T, et al.  Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Haematol. 2001;115:991–997
  22. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, et al.  Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002;99:11902–11907
  23. Matsumoto M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, et al: Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood (in press)
  24. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98:2730–2735
  25. Rougier N, Kazatchkine MD, Rougier J-P, Fremeaux-Bacchi V, Blouin J, Deschenes G, et al.  Human factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol. 1998;9:2318–2326
  26. Pèrez-Caballero D, Gonzàlez-Rubio C, Gallardo ME, Vera M, Lopez-Trascasa M, Rodriguez de CS, et al.  Clustering of the missence mutations in the C-terminal region of factor H in atypical uremic syndrome. Am J Hum Genet. 2001;68:478–484
  27. Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, et al.  Factor H mutations in hemolytic uremic syndrome cluster in exons 18–20, a domain for host cell recognition. Am J Hum Genet. 2001;68:485–490
  28. Ashida A, Nakamura H, Yoden A, Tamai H, Ishizashi H, Yagi H, et al.  Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS13); an important discrimination from Upshaw-Schulman syndrome. Am J Hematol. 2002;71:318–322
  29. van der Plas RM, Schiphorst ME, Huizinga EG, Hene RJ, Verdonck LF, Sxma JJ, et al.  von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenia purpura. Blood. 1999;93:3798–3802
  30. Tsai H-M, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased von Willebrand factor-platelet binding in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000;132:794–799
  31. Sugio Y, Okamura T, Shimoda K, Matsumoto M, Yagi H, Ishizashi H, et al.  Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol. 2001;74:347–351
  32. Amano SY, Inoue M, Yoshida Y, Yagi H, Ishizashi H, Matsumoto M, et al.  Intensive plasma IgG removal therapy for severe thrombotic thrombocytopenic pupura. Int J Hematol. 2002;76:474–476
  33. Yagi H, Narita N, Matsumoto M, Sakurai Y, Ikari H, Yoshioka A, et al.  Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157. Am J Hematol. 2001;66:105–115
  34. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600

☆ Supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (to H.I. and Y.F.) and for Blood Coagulation Abnormalities from the Ministry of Health and Welfare of Japan (to Y.F.).

PII: S0037-1963(03)00282-8

doi: 10.1053/j.seminhematol.2003.10.009

Seminars in Hematology
Volume 41, Issue 1 , Pages 68-74 , January 2004

Article Tools